Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
72
SLS Quote, Financials, Valuation and Earnings
Last price:
$2.78
Seasonality move
:
1.34%
Day range:
$2.41 - $2.66
52-week range:
$0.85 - $2.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.24x
Volume:
8.9M
Avg. volume:
5M
1-year change:
197.3%
Market cap:
$376M
Revenue:
--
EPS (TTM):
-$0.29
Analysts' Opinion
-
Consensus RatingSELLAS Life Sciences Group, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.83, SELLAS Life Sciences Group, Inc. has an estimated upside of 158.84% from its current price of $2.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $2.64.
Fair Value
-
According to the consensus of 2 analysts, SELLAS Life Sciences Group, Inc. has 158.84% upside to fair value with a price target of $6.83 per share.
SLS vs. S&P 500
-
Over the past 5 trading days, SELLAS Life Sciences Group, Inc. has overperformed the S&P 500 by 26.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
SELLAS Life Sciences Group, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SELLAS Life Sciences Group, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter SELLAS Life Sciences Group, Inc. reported revenues of --.
Earnings Growth
-
SELLAS Life Sciences Group, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter SELLAS Life Sciences Group, Inc. reported earnings per share of -$0.06.
Enterprise value:
332.2M
EV / Invested capital:
7.19x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-10.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-78.64%
Net Income Margin (TTM):
--
Return On Equity:
-103.86%
Return On Invested Capital:
-100.8%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$368K | -- | -- | -- | -- | |
| Operating Income | -$39.1M | -$32.8M | -$26.9M | -$7.3M | -$7.1M | |
| EBITDA | -$38.8M | -$32.8M | -$26.9M | -$7.3M | -$7.1M | |
| Diluted EPS | -$1.54 | -$0.70 | -$0.29 | -$0.10 | -$0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29M | $22.6M | $5.2M | $24M | $49.1M | |
| Total Assets | $38M | $26M | $8.1M | $26.5M | $51.6M | |
| Current Liabilities | $5.3M | $12.6M | $11.7M | $10.6M | $5.9M | |
| Total Liabilities | $11.3M | $13.4M | $11.9M | $10.6M | $5.9M | |
| Total Equity | $26.6M | $12.6M | -$3.8M | $15.9M | $45.6M | |
| Total Debt | $857K | $680K | $178K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31.7M | -$33.1M | -$30.6M | -$7.8M | -$7.1M | |
| Cash From Investing | -$5.5M | -- | -- | -- | -- | |
| Cash From Financing | $19.9M | $50.1M | $53.9M | $19.7M | $26.1M | |
| Free Cash Flow | -$36.2M | -$38.6M | -$30.6M | -$7.8M | -$7.1M | |
SLS
Sector
Market Cap
$376M
$28.4M
Price % of 52-Week High
99.25%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-26.79%
-1.49%
1-Year Price Total Return
197.3%
-16.67%
Beta (5-Year)
2.508
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.22
200-day SMA
Buy
Level
$1.67
Bollinger Bands (100)
Buy
Level
1.55 - 2.01
Chaikin Money Flow
Buy
Level
9.4M
20-day SMA
Buy
Level
$1.87
Relative Strength Index (RSI14)
Buy
Level
78.27
ADX Line
Buy
Level
19.93
Williams %R
Sell
Level
-1.6
50-day SMA
Buy
Level
$1.81
MACD (12, 26)
Buy
Level
0.54
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
19.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.0344)
Sell
CA Score
(Annual)
Level (-13.4121)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (13.2074)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, SLS has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLS average analyst price target in the past 3 months is $6.83.
-
Where Will SELLAS Life Sciences Group, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that SELLAS Life Sciences Group, Inc. share price will rise to $6.83 per share over the next 12 months.
-
What Do Analysts Say About SELLAS Life Sciences Group, Inc.?
Analysts are divided on their view about SELLAS Life Sciences Group, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SELLAS Life Sciences Group, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is SELLAS Life Sciences Group, Inc.'s Price Target?
The price target for SELLAS Life Sciences Group, Inc. over the next 1-year time period is forecast to be $6.83 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SELLAS Life Sciences Group, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SLS?
You can purchase shares of SELLAS Life Sciences Group, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SELLAS Life Sciences Group, Inc. shares.
-
What Is The SELLAS Life Sciences Group, Inc. Share Price Today?
SELLAS Life Sciences Group, Inc. was last trading at $2.78 per share. This represents the most recent stock quote for SELLAS Life Sciences Group, Inc.. Yesterday, SELLAS Life Sciences Group, Inc. closed at $2.64 per share.
-
How To Buy SELLAS Life Sciences Group, Inc. Stock Online?
In order to purchase SELLAS Life Sciences Group, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SLS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLS
Sector
P/E ratio
--
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
8.24x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
SLS
Sector
Revenue growth
--
4.62%
Earnings growth
39.87%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.08
-$0.21
Profitability
SLS
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-100.8%
-31.84%
Return on assets
-78.64%
-27.96%
Return on equity
-103.86%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
11
Balance Sheet
SLS
Sector
Total cash
$44.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$19.6M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.13% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.43% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 0.54% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
